
CLAIMS

What is claimed is:

1. A compound



or a pharmaceutically acceptable salt thereof.

2. A pharmaceutically acceptable salt of the compound of claim 1.

3. The pharmaceutically acceptable salt according to claim **2**, wherein the salt comprises a counterion selected from the group consisting of: hydrochloride, hydrobromide, hydrogensulphate, sulfate, phosphate, fumarats, succinate, oxalates and lactates, bisulfate, hydroxyl, tartrate, nitrate, citrate, bitartrate, carbonate, malate, maleate, fumarate sulfonate, methylsulfonate, formate, acetate, and carboxylate, p-toluene-sulfonate, benzenesulfonate, methanesulfonate, oxalate, succinate, tartrate, citrate, fumarate, glucuronate, ascorbate and maleate, ammonium, sodium, potassium, calcium, magnesium, zinc, lithium, methylamino, dimethylamino, diethylamino and triethylamino.

4. The pharmaceutically acceptable salt according to claim **2**, wherein the salt is a di-salt.

5. The pharmaceutically acceptable salt according to claim **4**, wherein the di-salt is a hydrochloride di-salt.

6. The pharmaceutically acceptable salt according to claim **4**, wherein the di-salt is a hydrobromide di-salt.

7. A pharmaceutical composition comprising a compound according to claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

8. The pharmaceutical composition of claim 7, wherein the composition is formulated for oral administration.

9. The compound of claim 1, or the pharmaceutically acceptable salt of any one of claims 2-6, or the pharmaceutical composition of any one of claims 7-8, for use in the treatment of cancer.


10. The pharmaceutically acceptable salt according to claim 9, wherein the salt comprises a counterion selected from the group consisting of: hydrochloride, hydrobromide, hydrogensulphate, sulfate, phosphate, fumarats, succinate, oxalates and lactates, bisulfate, hydroxyl, tartrate, nitrate, citrate, bitartrate, carbonate, malate, maleate, fumarate sulfonate, methylsulfonate, formate, acetate, and carboxylate, p-toluene-sulfonate, benzenesulfonate, methanesulfonate, oxalate, succinate, tartrate, citrate, fumarate, glucuronate, ascorbate and maleate, ammonium, sodium, potassium, calcium, magnesium, zinc, lithium, methylamino, dimethylamino, diethylamino and triethylamino.

11. The pharmaceutically acceptable salt according to claim 9, wherein the salt is a di-salt.

12. The pharmaceutically acceptable salt according to claim 11, wherein the di-salt is a hydrochloride di-salt.

13. The pharmaceutically acceptable salt according to claim 11, wherein the di-salt is a hydrobromide di-salt.

14. Use of a compound



or a pharmaceutically acceptable salt thereof in the manufacture of a pharmaceutical composition for the treatment of cancer.

15. The use according to claim 14, wherein the pharmaceutically acceptable salt comprises a counterion selected from the group consisting of: hydrochloride, hydrobromide, hydrogensulphate, sulfate, phosphate, fumarats, succinate, oxalates and lactates, bisulfate, hydroxyl, tartrate, nitrate, citrate, bitartrate, carbonate, malate, maleate, fumarate sulfonate, methylsulfonate, formate, acetate, and carboxylate, p-toluene-sulfonate, benzenesulfonate, methanesulfonate, oxalate, succinate, tartrate, citrate, fumarate, glucuronate, ascorbate and

maleate, ammonium, sodium, potassium, calcium, magnesium, zinc, lithium, methylamino, dimethylamino, diethylamino and triethylamino.

16. The use according to claim 14, wherein the pharmaceutically acceptable salt is a di-salt.

17. The use according to claim 16, wherein the di-salt is a hydrochloride di-salt.

18. The use according to claim 16, wherein the di-salt is a hydrobromide di-salt.